Cargando…

Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer

Chemotherapy is the main treatment for triple-negative breast cancer (TNBC), a subtype of breast cancer that is aggressive with a poor prognosis. While chemotherapeutics are potent, these agents lack specificity and are equally toxic to cancer and nonmalignant cells and tissues. Targeted therapies f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saghaeidehkordi, Azam, Chen, Shiuan, Yang, Sun, Kaur, Kamaljit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148172/ https://www.ncbi.nlm.nih.gov/pubmed/34063098 http://dx.doi.org/10.3390/pharmaceutics13050661

Ejemplares similares

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells
por: Hossein-Nejad-Ariani, Hanieh, et al.
Publicado: (2019)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

Keratin 19 binds and regulates cytoplasmic HNRNPK mRNA targets in triple-negative breast cancer
por: Fallatah, Arwa, et al.
Publicado: (2023)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
por: Avvakumova, S., et al.
Publicado: (2019)

Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer
por: Yuan, Shen-Jun, et al.
Publicado: (2019)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)

The development of activatable lytic peptides for targeting triple negative breast cancer
por: Zhao, Hui, et al.
Publicado: (2017)

Peptide density targets and impedes triple negative breast cancer metastasis
por: Liu, Daxing, et al.
Publicado: (2018)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Comparative Evaluation of the Cytotoxicity of Doxorubicin in BT-20 Triple-Negative Breast Carcinoma Monolayer and Spheroid Cultures
por: Ncube, Keith N., et al.
Publicado: (2023)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
por: Demeule, Michel, et al.
Publicado: (2021)

Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer
por: Li, Rui, et al.
Publicado: (2022)

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer
por: Obayemi, J. D., et al.
Publicado: (2020)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
por: Lothstein, Leonard, et al.
Publicado: (2020)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy
por: Zhou, Jingyi, et al.
Publicado: (2023)

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
por: Zeng, Weiwei, et al.
Publicado: (2023)

Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
por: Price, Lauren S.L., et al.
Publicado: (2021)

Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines
por: Puspitasari, Diah, et al.
Publicado: (2022)

Tumor Microenvironment Multiple Responsive Nanoparticles for Targeted Delivery of Doxorubicin and CpG Against Triple-Negative Breast Cancer
por: Gu, Fenfen, et al.
Publicado: (2022)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Synthesis, Characterization, and In Vitro Cytotoxicity Evaluation of Doxorubicin-Loaded Magnetite Nanoparticles on Triple-Negative Breast Cancer Cell Lines
por: Markhulia, Jano, et al.
Publicado: (2023)

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer
por: McKenna, Matthew T., et al.
Publicado: (2017)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells
por: Mentoor, Ilze, et al.
Publicado: (2021)

Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer
por: Lee, Kevin J, et al.
Publicado: (2021)

Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
por: Velenosi, Thomas J., et al.
Publicado: (2022)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

CD44-Receptor Targeted Gold-Doxorubicin Nanocomposite for Pulsatile Chemo-Photothermal Therapy of Triple-Negative Breast Cancer Cells
por: Kalyane, Dnyaneshwar, et al.
Publicado: (2022)

Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)

Development of CAPER peptides for the treatment of triple negative breast cancer
por: Chilewski, Shannon D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b1io56g0dkkpsqiin7n289jqca